Advertisement

IMP Dehydrogenase Mutants: Cell Culture Model for Hyperuricemia

  • Buddy Ullman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 165)

Abstract

Primary gout with associated hyperuricemia is a genetically heterogeneous disorder characterized by hyperuricemia due to increased rates of purine synthesis or enhanced cellular turnover. The genetic lesions which lead to enhanced rates of purine synthesis are mostly undefined. Several groups have reported that hyperuricemia can be associated with different types of kinetic alterations in the enzyme phosphoribosylpyrophosphate (PRPP) synthetase (1–3) or a deficiency in hypoxanthine-guanine phosphoribosyltransferase (4–5). The purine metabolic pathway is subject to a variety of control mechanisms including substrate availability, feedback inhibition of enzyme activity, compartmentalization of substrates and effectors, and regulation of enzyme levels. This biosynthetic pathway has two regulatory domains. The first occurs before the IMP branchpoint in which both PRPP synthetase and PRPP-glutamine amidotransferase are subject to allosteric inhibition by nucleotide effectors. The second regulatory domain occurs subsequent to IMP synthesis, where both adenylosuccinate synthetase and IMP dehydrogenase, the penultimate enzymes in AMP and GMP synthesis, respectively, are also regulated by ribonucleotide effectors. The genetic and metabolic heterogeneity of overproduction hyperuricemia suggests that defects in any one of these enzymes might lead to excessive rate of purine synthesis.

Keywords

Mutant Cell Cell Culture Model Mycophenolic Acid Purine Synthesis Primary Gout 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sperling, O., Boer, P., Persky-Brosh, S., Kanarek, E., and de Vries, A. (1972) Rev. Eur. Etud. Clin. Biol. 17, 703–706PubMedGoogle Scholar
  2. 2.
    Becker, M. A., Meyer, L. J., Wood, A. W., and Seegmiller, J. E. (1973) Science 179, 1123–1126PubMedCrossRefGoogle Scholar
  3. 3.
    Becker, M. A., Raivio, K. O., Bakay, B., Adams, W. B., and Nyhan, W. L. (1980) in Purine Metabolism in Man-III (Rapado, E., Watts, R. W. E., and De Bruyn, C. H. M. M., eds) Vol. 122A, pp. 387–392, Plenum Press, New YorkGoogle Scholar
  4. 4.
    Kelley, W. N., Green, M. L., Rosenbloom, F. M., Henderson, J. F., and Seegmiller, J. E. (1969) Ann. Intern. Med. 70, 155–206PubMedGoogle Scholar
  5. 5.
    Seegmiller, J. E., Rosenbloom, F. M., and Kelley, W. N. (1967) Science 155, 1682–1684PubMedCrossRefGoogle Scholar
  6. 6.
    Ullman, B., Clift, S. M., Cohen, A., Gudas, L. J., Levinson, B. B., Wormsted, M. A., and Martin, D. M., Jr. (1979) J. Cell. Physiol. 99, 139–152PubMedCrossRefGoogle Scholar
  7. 7.
    Ullman, B., Wormsted, M. A., Cohen, M. B., and Martin, D. W., Jr. Proc. Natl. Acad. Sci. U.S.A., in press.Google Scholar
  8. 8.
    Willis, R. C., and Seegmiller, J. E. (1980) in Purine Metabolism in Man-III (Sano, G. H., ed) Vol. 122B, pp. 237–242, Plenum Press, New YorkGoogle Scholar
  9. 9.
    Franklin, T. J., and Cook, J. M. (1969) Biochem. J. 113, 515–524PubMedGoogle Scholar
  10. 10.
    Sweeney, M. J., Hoffman, D. H., and Esterman, M. A. (1977) Cancer Res. 32, 1803–1809Google Scholar
  11. 11.
    Robins,R. K., and Simon, L. N. (1973) Proc. Natl. Acad. Sci. U.S.A. 70, 1174–1178PubMedCrossRefGoogle Scholar
  12. 12.
    Cohen, M. B., Maybaum, J., and Sadee, W. (1981) J. Biol. Chem. 256:8713–8717PubMedGoogle Scholar
  13. 13.
    Ullman, manuscript submitted.Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Buddy Ullman
    • 1
  1. 1.University of KentuckyLexingtonUSA

Personalised recommendations